Hematological Malignancies

Hematologic Malignancies

Powering better decisions for  you and your patients

Our comprehensive hematology test menu and expertise equip you with detailed reports and deep scientific insights to provide you with the most accurate diagnoses and risk stratifications for your patients.

supporting image

Expertise You Can Trust

45+

Over forty-five board-certified hemato-pathologists and PhD geneticists focus on our hematopathology services including results analysis, reporting, and consultative support.

375,000+

With over 375,000 hematology/oncology tests performed annually, you and your patients will benefit from our streamlined processes and expertise in the analysis and reporting of a vast variety of cases.

87%

Pivotal in the development of 87% of all drugs approved by the FDA in 2020, including 100% of the oncology drugs approved by the FDA.

Powering better decisions and bringing healthcare within reach for all

We offer a comprehensive portfolio of tests ranging from morphology and cytogenetics to single gene analysis and next-generation sequencing. 

Continuum of care

We use a pathway-driven approach to perform the most appropriate
tests for your patients. 

Initial TEsting

Initial Testing

  • Bone marrow / peripheral blood morphology
  • IHC
  • Flow cyometry
  • Cytogenetics
  • IntelliGEN® Myeloid

New Diagnosis, Treatment, Progression/Recurrence and Monitoring

  • Gene-specific molecular assays
  • FISH profiles
  • Individual FISH probes
  • Reveal® SNP Microarray
  • IntelliGEN® Myeloid
  • Qualitative/Quantitative PCR tests
  • clonoSEQ® Assay for MRD
New Diagnosis, Treatment, Progression/Recurrence and Monitoring

Pioneering Scientific Breakthroughs

Sponsored Testing Programs

HLA today

HLA Today

For patients with AML or high risk myelodysplastic syndrome (MDS). The program aims to improve patient outcomes by providing physicians with critical information as early as possible. Offered by the NMDP/Be The Match in partnership with LabCorp, high-resolution HLA typing results and a preliminary donor search report will be sent at no-charge to providers or patients.

Mature woman

Blueprint’s Biomarker Testing Program

No-charge KIT D816V testing for Systemic Mastocytosis provided by Labcorp Oncology for eligible patients through the sponsored testing program from Blueprint Medicines. Early biomarker testing using a non-invasive, highly sensitive, and quantitative KIT D816V test may reduce a patient’s time to diagnosis. 

Explore Our Test Menu

Our comprehensive menu features more than 450 single analyte and multi-marker tests to provide critical insights you need at every step of the patient journey.

Labcorp Lab

Meet Our Team

  • You can trust our team of hematopathology experts

    With decades of experience in hematopathology, our medical staff and laboratory professionals bring deep knowledge and wide-ranging technical expertise. Our experts are also available for consultation and follow-up queries on your patient’s report. 

    Learn More

To learn more, please contact us